Loading...
Imatinib-Resistant CML Cells Have Low ENT Activity but Maintain Sensitivity to Gemcitabine
Philadelphia chromosome-positive chronic myelogenus leukemia (CML) is widely treated with imatinib mesylate (imatinib), a potent inhibitor of the Bcr-Abl tyrosine kinase. However, resistance to this compound remains a concern. Current treatment approaches include combinations of imatinib with nucleo...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2008
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2702138/ https://ncbi.nlm.nih.gov/pubmed/18600540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15257770802145892 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|